MaxCyte Capex Per Share from 2010 to 2025

MXCT Stock  USD 3.15  0.06  1.94%   
MaxCyte Capex Per Share yearly trend continues to be comparatively stable with very little volatility. Capex Per Share is likely to outpace its year average in 2025. From the period from 2010 to 2025, MaxCyte Capex Per Share quarterly data regression had r-value of  0.48 and coefficient of variation of  179.99. View All Fundamentals
 
Capex Per Share  
First Reported
2010-12-31
Previous Quarter
0.01574642
Current Value
0.0226
Quarterly Volatility
0.04402649
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5 M, Interest Expense of 138.6 K or Selling General Administrative of 31.2 M, as well as many indicators such as Price To Sales Ratio of 10.73, Dividend Yield of 0.0 or PTB Ratio of 2.22. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
  
Check out the analysis of MaxCyte Correlation against competitors.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

Latest MaxCyte's Capex Per Share Growth Pattern

Below is the plot of the Capex Per Share of MaxCyte over the last few years. It is MaxCyte's Capex Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
Capex Per Share10 Years Trend
Slightly volatile
   Capex Per Share   
       Timeline  

MaxCyte Capex Per Share Regression Statistics

Arithmetic Mean0.02
Geometric Mean0.01
Coefficient Of Variation179.99
Mean Deviation0.02
Median0.01
Standard Deviation0.04
Sample Variance0
Range0.1813
R-Value0.48
Mean Square Error0
R-Squared0.23
Significance0.06
Slope0
Total Sum of Squares0.03

MaxCyte Capex Per Share History

2025 0.0226
2024 0.0157
2023 0.0358
2022 0.18
2021 0.0423
2020 0.0298
2019 0.0225

About MaxCyte Financial Statements

MaxCyte shareholders use historical fundamental indicators, such as Capex Per Share, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capex Per Share 0.02  0.02 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.